# Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

> **NCT04937660** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 185 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04937660
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-15
- **Primary completion:** 2025-04-29
- **Final completion:** 2025-04-29
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04937660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04937660, "Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04937660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*